The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $50.69

Today's change-0.08 -0.16%
Updated July 31 4:03 PM EDT. Delayed by at least 15 minutes.
 

Abbott Laboratories

NYSE: ABT
Last

(U.S.) $50.69

Today's change-0.08 -0.16%
Updated July 31 4:03 PM EDT. Delayed by at least 15 minutes.

Abbott Laboratories down (U.S.)$0.08

Abbott Laboratories closed lower Friday, dropping (U.S.)$0.08 or 0.16% to (U.S.)$50.69. Shares have lost 0.71% over the last five days, but sit 2.03% below their 52-week high. This security has outperformed the S&P 500 by 11.38% during the last year.

Key company metrics

  • Open(U.S.) $51.07
  • Previous close(U.S.) $50.77
  • High(U.S.) $51.13
  • Low(U.S.) $50.60
  • Bid / Ask-- / --
  • YTD % change+12.59%
  • Volume5,573,486
  • Average volume (10-day)5,827,825
  • Average volume (1-month)5,379,414
  • Average volume (3-month)4,961,503
  • 52-week range(U.S.) $39.28 to (U.S.) $51.74
  • Beta0.65
  • Trailing P/E32.16×
  • P/E 1 year forward23.42×
  • Forward PEG2.64×
  • Indicated annual dividend(U.S.) $0.96
  • Dividend yield1.89%
  • Trailing EPS(U.S.) $1.58
Updated July 31 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+11.67%

Based on its net profit margin of 11.67%, Abbott Laboratories is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.60%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue5,1704,8975,2905,104
Total other revenue--------
Total revenue5,1704,8975,2905,104
Gross profit2,9522,8172,9862,778
Total cost of revenue2,2182,0802,3042,326
Total operating expense4,4414,2874,4814,373
Selling / general / administrative1,7271,7301,7131,566
Research & development345313346305
Depreciation / amortization151156163132
Interest expense (income), net operating--------
Unusual expense (income)--8-4544
Other operating expenses, total--------
Operating income729610809731
Interest income (expense), net non-operating-17-37-43-35
Gain (loss) on sale of assets--------
Other--------
Income before tax986653802718
Income after tax786529632440
Income tax, total200124170278
Net income7842,292904538
Total adjustments to net income--------
Net income before extra. items786529632440
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items786529632440
Inc. avail. to common incl. extra. items7842,292904538
Diluted net income7842,292904538
Dilution adjustment--------
Diluted weighted average shares1,5041,5161,5221,520
Diluted EPS excluding extraordinary itemsvalue per share0.520.350.420.29
Dividends per sharevalue per share0.240.240.240.22
Diluted normalized EPSvalue per share0.520.350.390.31